Thoracic Cancer MSK 20-415

Stereotactic Body Radiation Therapy with Consolidation Durvalumab in High-Risk Early-Stage Non-Small Cell Lung Cancer – A Phase II Single-Arm Trial

The purpose of this study is to find out whether treatment with the study drug durvalumab combined with a type of radiation therapy called stereotactic body radiation (SBRT) is a more effective treatment for early-stage non-small cell lung cancer (NSCLC) than SBRT alone.

Eligibility Criteria:

  • Histologically or cytologically confirmed early-stage NSCLC (T1-4N0M0)
  • Ineligible for resection due to functional status, tumor size, or medical comorbidities or unwilling to undergo surgical resection
  • Any level of PD-L1 expression and Candidates for definitive SBRT
  • At least 40% risk for disease progression based on MSKCC risk prediction model
  • No Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • No Previous thoracic radiation precluding definitive SBRT

This study is for patients age 18 and older.

Available at: Hartford Hospital, Hospital of Central Connecticut, Midstate Medical Center.